1.Magnetic Resonance Imaging and GeneXpert: A Rapid and Accurate Diagnostic Tool for the Management of Tuberculosis of the Spine.
Ayush SHARMA ; Harvinder Singh CHHABRA ; Rajat MAHAJAN ; Tarun CHABRA ; Sahil BATRA
Asian Spine Journal 2016;10(5):850-856
STUDY DESIGN: Retrospective study. PURPOSE: The aim of this study was to analyze various diagnostic tools, including GeneXpert, for the management of tuberculosis of the spine. OVERVIEW OF LITERATURE: Traditional diagnostic methods of microscopy, histology, and culture have low sensitivity and specificity for the management of tuberculosis of the spine. METHODS: Of the 262 treated cases of spinal tuberculosis, data on 1 year follow-up was available for 217 cases. Of these, only 145 cases with a confirmed diagnosis were selected for retrospective analysis. RESULTS: In 145 of the 217 patients (66.80%), diagnosis was confirmed on the basis of a culture. Of the 145 patients with a confirmed diagnosis, 98 (66.20%) patients were diagnosed on the basis of clinical presentation, whereas 123 (84.8%) exhibited a typical magnetic resonance imaging (MRI) picture. In 99 surgically treated patients, the diagnosis was confirmed on the basis of an intraoperative tissue biopsy. Among the 46 patients treated conservatively, 35 underwent a transpedicular biopsy, 4 patients underwent computed tomography-guided biopsy, 6 patients were diagnosed on the basis of material obtained from a cold abscess, and 1 patient underwent an open biopsy. The sensitivity of the culture for the detection of Mycobacterium tuberculosis was 66.80% (145/217) in our patients. Among the cases in which GeneXpert was used, the sensitivity for the detection of Mycobacterium tuberculosis was 93.4% (43/46). Moreover, the sensitivity of GeneXpert to detect rifampicin resistance was 100% (7/7) in our study. CONCLUSIONS: Majority of the patients with tuberculosis of the spine can be diagnosed on the basis of a typical radiological presentation via MRI. In our study, 84.8% cases exhibited typical MRI findings. For patients presenting with atypical MRI features, a rapid and accurate diagnosis is possible by combining GeneXpert with MRI. The combined use of MRI and GeneXpert is a rapid and highly sensitive tool to diagnose tuberculosis and rifampicin resistance in patients with tuberculosis of the spine. Furthermore, we achieved a 97.9% sensitivity for the detection of Mycobacterium tuberculosis and 100% sensitivity for the detection of rifampicin resistance in our study.
Abscess
;
Biopsy
;
Diagnosis
;
Follow-Up Studies
;
Humans
;
Magnetic Resonance Imaging*
;
Microscopy
;
Mycobacterium tuberculosis
;
Retrospective Studies
;
Rifampin
;
Sensitivity and Specificity
;
Spine*
;
Tuberculosis*
;
Tuberculosis, Spinal
2.2,3-Diaryl-3-imidazo4,5-pyridine derivatives as potential anticancer and anti-inflammatory agents.
Erin Marie KIRWEN ; Tarun BATRA ; Chandrabose KARTHIKEYAN ; Girdhar Singh DEORA ; Vandana RATHORE ; ; Chaitanya MULAKAYALA ; Naveen MULAKAYALA ; Amy Catherine NUSBAUM ; Joel CHEN ; Haneen AMAWI ; Kyle MCINTOSH ; Sahabjada ; Neelam SHIVNATH ; Deepak CHOWARSIA ; Nisha SHARMA ; Md ARSHAD ; Piyush TRIVEDI ; Amit K TIWARI
Acta Pharmaceutica Sinica B 2017;7(1):73-79
In this study we examined the suitability of the-imidazo[4,5-]pyridine ring system in developing novel anticancer and anti-inflammatory agents incorporating a diaryl pharmacophore. Eight 2,3-diaryl-3-imidazo[4,5-]pyridine derivatives retrieved from our in-house database were evaluated for their cytotoxic activity against nine cancer cell lines. The results indicated that the compounds showed moderate cytotoxic activity against MCF-7, MDA-MB-468, K562 and SaOS2 cells, with K562 being the most sensitive among the four cancer cell lines. The eight 2,3-diaryl-3-imidazo[4,5-]pyridine derivatives were also evaluated for their COX-1 and COX-2 inhibitory activity. The results showed that compoundexhibited 2-fold selectivity with ICvalues of 9.2 and 21.8 µmol/L against COX-2 and COX-1, respectively. Molecular docking studies on the most active compoundrevealed a binding mode similar to that of celecoxib in the active site of the COX-2 enzyme.